GlassScriptPhysician profile
Joel Mccormick
NPI 1568924025
$2,803.59
in general payments reported to CMS, 2019-2025
14 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $198 · 2021: $129 · 2022: $260 · 2023: $125 · 2024: $1,829 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Travel and Lodging: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.03 |
| Travel and Lodging | $798.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,221.40 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $345.01 | 2020-2023 | Dupixent |
| Glaxosmithkline, LLC. | $231.84 | 2022-2025 | Nucala |
| Becton, Dickinson and Company | $208.67 | 2024 | Pristine, Powerpicc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.52 | 2022-2024 | |
| Grifols USA, LLC | $124.98 | 2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $124.74 | 2024 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $124.74 | 2024 | Tezspire |
| Amgen INC. | $113.13 | 2021 | |
| Novo Nordisk INC | $93.75 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.85 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.82 | 2021 | |
| Mannkind Corporation | $15.44 | 2022 | |
| Upsher-Smith Laboratories LLC | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.